Medicure Inc. (MPH.V)
CAD 0.89
(14.1%)
CAD 0.89
(14.1%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 21.69 Million CAD | -5.94% |
| 2022 | 23.06 Million CAD | 6.08% |
| 2021 | 21.74 Million CAD | 87.29% |
| 2020 | 11.61 Million CAD | -42.45% |
| 2019 | 20.17 Million CAD | -30.7% |
| 2018 | 29.1 Million CAD | 7.28% |
| 2017 | 27.13 Million CAD | -28.18% |
| 2016 | 37.77 Million CAD | 71.07% |
| 2015 | 22.08 Million CAD | 144.7% |
| 2014 | 9.02 Million CAD | 78.68% |
| 2013 | 5.05 Million CAD | 94.06% |
| 2012 | 2.6 Million CAD | -45.74% |
| 2011 | 4.79 Million CAD | 32.21% |
| 2010 | 3.62 Million CAD | 9.38% |
| 2009 | 3.31 Million CAD | -30.79% |
| 2008 | 4.79 Million CAD | 113.27% |
| 2007 | 2.24 Million CAD | -62.2% |
| 2006 | 5.94 Million CAD | 1883.32% |
| 2005 | 299.73 Thousand CAD | -34.73% |
| 2004 | 459.19 Thousand CAD | 3.08% |
| 2003 | 445.46 Thousand CAD | 84.62% |
| 2002 | 241.28 Thousand CAD | 31.19% |
| 2001 | 183.91 Thousand CAD | 35.36% |
| 2000 | 135.86 Thousand CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.69 Million CAD | 12.29% |
| 2024 Q2 | 5.16 Million CAD | -9.29% |
| 2023 Q2 | 5.99 Million CAD | 6.49% |
| 2023 FY | 21.69 Million CAD | -5.94% |
| 2023 Q1 | 5.62 Million CAD | -10.88% |
| 2023 Q3 | 5 Million CAD | -16.54% |
| 2023 Q4 | 5.07 Million CAD | 1.38% |
| 2022 Q4 | 6.31 Million CAD | 19.44% |
| 2022 Q3 | 5.28 Million CAD | -8.0% |
| 2022 Q2 | 5.74 Million CAD | 0.54% |
| 2022 Q1 | 5.71 Million CAD | -15.98% |
| 2022 FY | 23.06 Million CAD | 6.08% |
| 2021 Q2 | 5.08 Million CAD | 3.04% |
| 2021 Q4 | 6.8 Million CAD | 38.3% |
| 2021 Q1 | 4.93 Million CAD | 107.83% |
| 2021 FY | 21.74 Million CAD | 87.29% |
| 2021 Q3 | 4.91 Million CAD | -3.28% |
| 2020 Q3 | 3.54 Million CAD | 32.62% |
| 2020 FY | 11.61 Million CAD | -42.45% |
| 2020 Q1 | 3.01 Million CAD | -13.33% |
| 2020 Q2 | 2.67 Million CAD | -11.1% |
| 2020 Q4 | 2.37 Million CAD | -33.08% |
| 2019 Q1 | 4.88 Million CAD | -38.19% |
| 2019 FY | 20.17 Million CAD | -30.7% |
| 2019 Q2 | 6.3 Million CAD | 29.12% |
| 2019 Q3 | 5.51 Million CAD | -12.41% |
| 2019 Q4 | 3.47 Million CAD | -37.07% |
| 2018 Q3 | 7.34 Million CAD | -5.77% |
| 2018 FY | 29.1 Million CAD | 7.28% |
| 2018 Q1 | 6.06 Million CAD | 20.61% |
| 2018 Q4 | 7.89 Million CAD | 7.41% |
| 2018 Q2 | 7.8 Million CAD | 28.63% |
| 2017 Q3 | 7.03 Million CAD | -65.4% |
| 2017 FY | 27.13 Million CAD | -28.18% |
| 2017 Q1 | 8.7 Million CAD | -44.91% |
| 2017 Q4 | 5.02 Million CAD | -28.55% |
| 2017 Q2 | 20.33 Million CAD | 133.57% |
| 2016 Q3 | 8.2 Million CAD | 6.51% |
| 2016 Q2 | 7.7 Million CAD | 26.92% |
| 2016 FY | 37.77 Million CAD | 71.07% |
| 2016 Q1 | 6.06 Million CAD | -36.3% |
| 2016 Q4 | 15.8 Million CAD | 92.65% |
| 2015 Q2 | 3.8 Million CAD | 13.89% |
| 2015 Q4 | 9.52 Million CAD | 75.91% |
| 2015 Q1 | 3.33 Million CAD | 0.0% |
| 2015 FY | 22.08 Million CAD | 144.7% |
| 2015 Q3 | 5.41 Million CAD | 42.46% |
| 2014 Q3 | 2.12 Million CAD | 18.57% |
| 2014 Q2 | 1.79 Million CAD | 9.33% |
| 2014 Q1 | 1.63 Million CAD | 88.15% |
| 2014 FY | 9.02 Million CAD | 78.68% |
| 2013 Q2 | 766.93 Thousand CAD | 71.41% |
| 2013 FY | 5.05 Million CAD | 94.06% |
| 2013 Q4 | 871.45 Thousand CAD | 16.66% |
| 2013 Q3 | 747.01 Thousand CAD | -2.6% |
| 2013 Q1 | 447.41 Thousand CAD | -37.94% |
| 2012 Q1 | 659.87 Thousand CAD | -70.63% |
| 2012 Q2 | 371.05 Thousand CAD | -43.77% |
| 2012 Q3 | 667.43 Thousand CAD | 79.88% |
| 2012 Q4 | 720.91 Thousand CAD | 8.01% |
| 2012 FY | 2.6 Million CAD | -45.74% |
| 2011 Q2 | 774.12 Thousand CAD | -36.63% |
| 2011 Q3 | 1.51 Million CAD | 96.26% |
| 2011 Q4 | 2.24 Million CAD | 47.87% |
| 2011 Q1 | 1.22 Million CAD | 52.23% |
| 2011 FY | 4.79 Million CAD | 32.21% |
| 2010 Q3 | 830.2 Thousand CAD | 37.71% |
| 2010 Q4 | 802.4 Thousand CAD | -3.35% |
| 2010 FY | 3.62 Million CAD | 9.38% |
| 2010 Q1 | 795.96 Thousand CAD | -18.55% |
| 2010 Q2 | 602.85 Thousand CAD | -24.26% |
| 2009 Q2 | 677.88 Thousand CAD | -54.38% |
| 2009 Q3 | 940.96 Thousand CAD | 38.81% |
| 2009 Q4 | 977.29 Thousand CAD | 3.86% |
| 2009 FY | 3.31 Million CAD | -30.79% |
| 2009 Q1 | 1.48 Million CAD | 1.91% |
| 2008 Q4 | 1.45 Million CAD | 24.52% |
| 2008 Q3 | 1.17 Million CAD | 57.98% |
| 2008 FY | 4.79 Million CAD | 113.27% |
| 2008 Q1 | 702.87 Thousand CAD | 116.68% |
| 2008 Q2 | 741.14 Thousand CAD | 5.45% |
| 2007 Q4 | 324.37 Thousand CAD | -32.24% |
| 2007 Q2 | 1.72 Million CAD | -31.67% |
| 2007 Q1 | 2.52 Million CAD | 77.78% |
| 2007 FY | 2.24 Million CAD | -62.2% |
| 2007 Q3 | 478.73 Thousand CAD | -72.22% |
| 2006 Q1 | - CAD | -100.0% |
| 2006 Q4 | 1.41 Million CAD | 406.74% |
| 2006 Q2 | - CAD | 0.0% |
| 2006 Q3 | 279.98 Thousand CAD | 0.0% |
| 2006 FY | 5.94 Million CAD | 1883.32% |
| 2005 Q3 | 37.17 Thousand CAD | -67.45% |
| 2005 Q4 | 34.68 Thousand CAD | -6.71% |
| 2005 FY | 299.73 Thousand CAD | -34.73% |
| 2005 Q1 | 214.3 Thousand CAD | 121.01% |
| 2005 Q2 | 114.19 Thousand CAD | -46.72% |
| 2004 Q4 | 96.97 Thousand CAD | -8.97% |
| 2004 FY | 459.19 Thousand CAD | 3.08% |
| 2004 Q2 | 128.08 Thousand CAD | -21.21% |
| 2004 Q3 | 106.52 Thousand CAD | -16.83% |
| 2004 Q1 | 162.55 Thousand CAD | 101.61% |
| 2003 FY | 445.46 Thousand CAD | 84.62% |
| 2003 Q1 | 68.73 Thousand CAD | 0.0% |
| 2003 Q2 | 47.83 Thousand CAD | -30.41% |
| 2003 Q4 | 80.62 Thousand CAD | 8.65% |
| 2003 Q3 | 74.2 Thousand CAD | 55.12% |
| 2002 Q3 | 67.45 Thousand CAD | 0.0% |
| 2002 FY | 241.28 Thousand CAD | 31.19% |
| 2002 Q4 | - CAD | -100.0% |
| 2001 FY | 183.91 Thousand CAD | 35.36% |
| 2000 FY | 135.86 Thousand CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 254.89 Thousand CAD | -8410.922% |
| CanadaBis Capital Inc. | 22.22 Million CAD | 2.378% |
| Decibel Cannabis Company Inc. | 115.95 Million CAD | 81.292% |
| Delivra Health Brands Inc. | 12.37 Million CAD | -75.263% |
| Entourage Health Corp. | 40.71 Million CAD | 46.715% |
| Lifeist Wellness Inc. | 21.65 Million CAD | -0.158% |
| Cannara Biotech Inc. | 57.26 Million CAD | 62.113% |
| PharmaCielo Ltd. | 1.54 Million CAD | -1307.103% |
| Rubicon Organics Inc. | 40.11 Million CAD | 45.922% |
| BioSyent Inc. | 31.59 Million CAD | 31.327% |
| Voyageur Pharmaceuticals Ltd. | - CAD | -Infinity% |